ArticleJournal of Korean medical science2025
Prevalence and Incidence of Ethambutol-Induced Optic Neuropathy and Its Risk Factors in Korea: A Nationwide Population-Based Study.
Article in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal Observation by Optical Coherence Tomography in Patients Treated with Ethambutol: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA national study was conducted using data from the National Health Insurance database to determine the prevalence, incidence, and risk factors for ethambutol-induced optic neuropathy (EON) in South Korea.
methodsThis retrospective population-based study was conducted from 2011 to 2020. The participants were identified via registered prescription codes between 2011 and 2018. Individuals with records mimicking EON or individuals diagnosed with EON at least once were excluded. A total of 315,888 patients were divided into a case group (EON) and a control group (non-EON).
resultsAmong 315,888 participants aged > 20 years, 2,703 cases of EON were identified, including 1,438 females (53.2%) and 1,265 males (46.8%). The estimated prevalence of EON was 8.54 cases per 1,000 persons (95% confidence interval [CI], 8.53-8.55), and the incidence was 159.16 cases per 100,000 person-years (95% CI, 153.27-165.28). The overall male-female ratio was 0.65 for prevalence and 0.69 for incidence. EON patients were more likely to be older (adjusted odds ratio [OR], 1.88; 95% CI, 1.38-2.58), have diabetes (adjusted OR, 1.14; 95% CI, 1.03-1.26), and have renal diseases (without end-stage renal disease [ESRD], adjusted OR = 1.64, 95% CI, 1.3-2.06; with ESRD, adjusted OR, 2.69; 95% CI, 1.92-3.76) than non-EON patients were. Patients with an EMB prescription duration ≥ 6 months had an elevated risk of EON compared with those with a prescription duration < 2 months (OR, 1.44; 95% CI, 1.30-1.60, adjusted for age, sex, hypertension, diabetes, and renal diseases).
conclusionThe cumulative incidence of EON was 0.9%. The prevalence and incidence rates of EON were higher among women than men. Age, diabetes, renal diseases, and duration of EMB prescription were risk factors for developing EON. These findings could be valuable for the prevention or early management of EON patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.